Loading
Loading
Curated from FDA notices, manufacturer press releases, peer-reviewed studies, and trusted outlets. Direct source links on every item. Practical context for researchers — not academic abstracts.
The FDA has removed Epitalon from its Category 2 'significant safety concerns' list and scheduled it for review by the Pharmacy Compounding Advisory Committee on July 24, 2026. The committee will evaluate safety, clinical utility, and suitability for pharmacy compounding — a positive recommendation could restore broader legitimate access to this tetrapeptide, which has decades of research behind its proposed telomere-lengthening and longevity effects.
Read source →STAT News surveys the rapidly evolving GLP-1 weight loss market — Novo Nordisk's Wegovy and Eli Lilly's Zepbound remain dominant, but Pfizer, Amgen and others are racing to compete. The report covers what the current leaders are developing to hold their ground and where the next wave of innovation is headed.
Read source →Full Phase 3 TRIUMPH-1 data confirm retatrutide's headline weight loss figures — up to 30.3% average reduction — along with significant BMI improvements in patients with obesity or overweight. Detailed dosing and safety data presented alongside the topline numbers.
Read source →ADA 2026 coverage highlights next-generation GLP-1 developments including triple hormone receptor agonists and longer-acting formulations targeting monthly or less-frequent dosing. Full trial data still pending for most candidates.
Read source →STAT News traces BPC-157's origins in researcher Predrag Sikiric's lab through its current widespread use in fitness and biohacking communities. The article examines the gap between preclinical research interest and the absence of approved human studies, and BPC-157's regulatory grey-area status.
Read source →Eli Lilly announced that retatrutide met its primary endpoint in the TRIUMPH-1 Phase 3 obesity trial, with weight loss described as 'powerful' — initial release ahead of full data disclosure at ADA 2026.
Read source →New England Journal of Medicine publishes a comprehensive review of GLP-1 receptor agonists as incretin analogues, covering mechanism of action, cardiovascular outcomes data, and the expanding therapeutic role across obesity, T2DM, and metabolic disease.
Read source →New data from Lilly suggests patients who stop GLP-1 agonists regain significant weight, supporting the case for long-term maintenance dosing strategies rather than finite treatment courses.
Read source →Survodutide (GLP-1/glucagon dual agonist) achieved weight loss analysts described as 'Wegovy-like' and showed signs of muscle mass preservation — a potential differentiator from existing GLP-1 drugs.
Read source →The FDA has scheduled an advisory committee meeting on unapproved peptides used in compounding, signalling a potential policy shift following pressure from HHS Secretary RFK Jr.
Read source →Lilly's orforglipron became the first daily GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, removing a key compliance barrier of existing oral GLP-1 options.
Read source →STAT News opinion piece on the rise of consumer peptide use — arguing that distrust of pharmaceutical medicine is driving patients toward compounds with weaker evidence bases.
Read source →In a notable regulatory shift, the FDA has reclassified several unapproved peptides previously barred from compounding, ahead of a formal advisory committee review on their potential compounding use.
Read source →Retatrutide lowered HbA1c by an average of 1.7–2.0% across doses at 40 weeks in TRANSCEND-T2D-1, meeting its primary endpoint and advancing the compound toward potential regulatory submission.
Read source →Retatrutide's Phase 3 diabetes data show the compound may be a meaningful advance on existing GLP-1 drugs — cutting blood sugar and body weight significantly in the TRANSCEND-T2D-1 study.
Read source →Eli Lilly issued a public warning after uncovering significant levels of impurity in compounded tirzepatide products mixed with vitamin B12, urging patients to avoid these formulations.
Read source →Eli Lilly's Phase 3 TRIUMPH-4 trial, evaluating retatrutide in patients with obesity, reported positive topline results — further supporting retatrutide's position as the most potent weight-loss agent in late-stage development.
Read source →Where this news comes from
Capital Peptides aggregates research news from primary sources only — FDA Federal Register notices, manufacturer investor releases, peer-reviewed studies on PubMed / NEJM / Lancet, and trusted industry outlets (BioPharma Dive, STAT, AJMC, HCPLive). We summarize in plain English; click the source link to verify. No vendor sponsorship influences inclusion.